Burning Rock Biotech (NASDAQ:BNR) Issues Quarterly Earnings Results, Beats Estimates By $0.32 EPS

Burning Rock Biotech (NASDAQ:BNR - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($1.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.40) by $0.32, Zacks reports. Burning Rock Biotech had a negative net margin of 83.50% and a negative return on equity of 60.68%. The company had revenue of $17.27 million during the quarter.

Burning Rock Biotech Trading Down 3.8 %

Shares of NASDAQ BNR traded down $0.18 during trading hours on Friday, reaching $4.52. The stock had a trading volume of 3,270 shares, compared to its average volume of 14,417. The firm has a 50-day moving average of $6.16 and a 200-day moving average of $5.28. The firm has a market cap of $46.30 million, a price-to-earnings ratio of -1.51 and a beta of 0.55. Burning Rock Biotech has a fifty-two week low of $2.62 and a fifty-two week high of $8.99.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.